Lv24
176 积分 2024-01-29 加入
Time-resolved fluorescent proteins expand fluorescent microscopy in temporal and spectral domains
21小时前
已完结
Therapeutic potential of targeting polo-like kinase 4
9天前
已完结
Role of PLK4 inhibition in cancer therapy
9天前
已完结
A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers
16天前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
20天前
已完结
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236
20天前
已完结
Luvometinib: First Approval
23天前
已完结
The Discovery of Polo-Like Kinase 4 Inhibitors: Identification of (1R,2S)-2-(3-((E)-4-(((cis)-2,6-Dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5′-methoxyspiro[cyclopropane-1,3′-indolin]-2′-one (CFI-400945) as a Potent, Orally Active Antitumor Agent
29天前
已完结
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018-present)
30天前
已完结
Design, synthesis and characterisation of a novel type II B-RAF paradox breaker inhibitor
1个月前
已完结
皖公网安备34019202002308
